About two and a half years after originating the role of chief commercial officer at Arvinas, John Northcott is leaving his post at the biotech. The change is effective immediately, according to ...

CEO John Houston emphasized that Arvinas is nearing key milestones, including the first Phase 3 topline data for vepdegestrant (vepdeg) from the VERITAC-2 trial expected in Q1 2025. He noted that this ...

Reports Q4 revenue $59.2M, consensus $62.79M. “We made significant progress across our pipeline in 2024, all of which we believe supports our ...